Year: 2006
Type: review
Abstract: Parkinson disease (PD) is a chronic, progressive neurodegenerative disorder that affects at least 1% of people by age 70 (1-3).James Parkinson provided the first detailed description of the disease in his 1817 monograph "An Essay on the Shaking Palsy."In the latter part of the nineteenth century, Charcot further refined the description of this disorder and identified the cardinal clinical features of PD including rest tremor, rigidity, balance impairment, and slowness of movement (reviewed in ref. 4).An early clue to the pathology of the disease came from Brissaud, who speculated that damage in the substantia nigra (SN) might lead to PD (5, 6).Eosinophilic inclusions (Lewy bodies) later were identified in the brains of PD patients (7) and, along with abnormalities in the SN, became a recognized pathologic marker of the disease (8).A major advance in the understanding of PD came when dopamine deficiency was discovered in the corpus striatum and SN of brains taken from patients (9).Later studies demonstrated the connection between the SN and the striatum, thus suggesting that dopaminergic cell loss in the SN directly leads to dopaminergic deficiency in the striatum (10).The determination that PD is a disease of dopamine loss led to the development of ratio-nal therapies aimed at correcting this deficiency (11).After some initial uncertainty, the dopamine precursor levodopa proved to be a powerful PD treatment (12).Subsequent advances in therapy included combining levodopa with a peripheral decarboxylase inhibitor, such as carbidopa or benserazide (13, 14).This combination significantly reduced the nausea and vomiting associated with levodopa therapy and allowed a greater proportion of levodopa to enter the brain.Similarly, catechol-O-methyltransferase (COMT) inhibitors, which prolong the half-life of levodopa and dopamine were found to enhance the effect of a given levodopa dose (15-17).In addition to increasing the level of dopamine precursors, the focus of therapeutic design was also on limiting the breakdown of endogenous dopamine.The monoamine oxidase type B (MAO-B) inhibitor selegiline works in this fashion and provides symptomatic benefit (18).Finally, the development of dopamine agonists that directly stimulate postsynaptic dopamine receptors, thus bypassing dopamine synthesis completely, further illustrates how novel therapies can be borne from knowledge of pathology (19,20).Surgical therapies that reduce tremor and rigidity in PD patients were used prior to the advent of levodopa treatment.Meyers pioneered surgical lesioning procedures that targeted symptoms and spared patients from the hemiparesis that resulted from earlier surgical approaches.These procedures largely were abandoned once levodopa therapy became more common (21).Recent advances in the understanding of basal ganglia physiology and the development of new technologies has led to a reemergence of surgical PD therapies in the form of deep brain stimulation (DBS) (22,23).DBS has become increasingly common in patients whose disease is difficult to manage with medical therapy alone.Despite these landmark advances in symptomatic PD therapy, the ability of these treatments to facilitate an acceptable quality of life for the patient wanes with time.This is due to the development of motor complications including wearing-off (the Diagnosis and treatment of Parkinson disease: molecules to medicine
DOI: 10.1172/jci29178
Authors: J. M. Savitt, Valina L Dawson, Ted M Dawson
Institutions: Johns Hopkins University, Johns Hopkins Medicine
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W1986118996
